Navigation Links
Columbia scientists develop cancer terminator viruses

irus did, this virus carried a gene called mda-7/IL-24, a novel gene identified and cloned in Dr. Fisher's laboratory, which is selectively toxic to cancer cells and is now in phase II clinical trials as a cancer gene therapeutic.

"We are extremely excited about these results and the prospect of one day using a form of the cancer terminator virus in human clinical trials," said Dr. Fisher, the study's senior author. "While the results of these trials need to be investigated further and replicated in future trials, we believe that viral-based therapies will someday soon be a standard part of the cancer armamentarium."

About the "Terminator" Viruses

The "terminator" viruses have the potential to become effective treatments for a wide range of tumors - such as ovarian, pancreatic, breast, brain (glioma), prostate, skin (melanoma) and colon cancer - because the virus is constructed to exploit a characteristic of all solid cancers. However, clinical trials are necessary before such treatments can be approved by the U.S. Food and Drug Administration and available for patients.

These publications are a continuation of research published in the Jan. 25, 2005 issue of PNAS, where the same research team, also led by Dr. Fisher, incorporated gene therapy into a specially designed non-replicating virus to overcome one of the major hurdles of gene therapy: its tendency to kill normal cells in the process of eradicating cancer cells. The virus eradicated prostate cancer cells in the lab and in animals, while leaving normal cells unscathed.

The present cancer "terminator" viruses represent the next generation of therapeutic viruses that permit replication uniquely in cancer cells with simultaneous production of immune modulating and toxic genes. These viruses effectively eliminate primary tumors and distant tumors (metastases) without harming normal cells or tissues.

Dr. Fisher's cancer research team includes Columbia Un
'"/>

Source:Columbia University Medical Center


Page: 1 2 3

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. Columbia study shows widely used artery clearing device does not help patients during heart attack
3. Contaminants linked to sturgeon decline in Columbia river
4. Columbia University licenses next-generation DNA sequencing technology
5. New bird discovered on unexplored Columbian mountain
6. Columbia scientists determine 3-dimensional structure of cells fuel gauge
7. Wisconsin scientists grow critical nerve cells
8. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
9. UAB scientists discover the origin of a mysterious physical force
10. Fox Chase Cancer Center scientists identify immune-system mutation
11. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.

Post Your Comments:
(Date:11/23/2009)... 23, 2009 Applied mathematicians dissected the mo..., a characteristic long leaf with a saddle-like ar...edges. The simple cause of the lily,s fan-like sha... differential growthwas revealed by using an equal...Haiyi Liang, a postdoctoral student at Harvard,s S...
(Date:11/23/2009)...0 participants gathered this week for the seventh ...conference. This year,s topic, "Synthetic Biology,...cal researchers to explore the engineering, scient...ield of synthetic biology. , Bonnie L. Bassler, ...sity and this year,s conference chair, challenged ...
(Date:11/23/2009)...vaccine available for the H1N1 virus has been sent.... The vaccination marks the first time vaccine has...emic flu., Iowa State University,s Hank Harris, ... this summer and has been shipping preventive dose...for several weeks., The latest vaccines were shi...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Apes Love a Good Laugh Too 47960 1Apes Love a Good Laugh Too 47960 2Apes Love a Good Laugh Too 47960 3Palliative Medicine to be official journal of the Association for Palliative Medicine 47956 1FAO IAEA Symposium to address animal production and health 8720 1FAO IAEA Symposium to address animal production and health 8720 2
...versity of New Hampshire (UNH) have found that inv...ange in blue mussels in as little as 15 years. The... associate professor of zoology James Byers and pu...e, indicates that such a response can evolve in an... of years previously assumed. The paper is called ...
... by the United Nations shows the need for an inter...estructive fishing practices that damage deep sea ... U.N. Division for Ocean Affairs and Law of the Se...able deep oceans of the high seas ?the 64 percent ...ns of any individual nation. Its review, ordered b...
...e Children,s Research Hospital have announced that...one antigenic variant of the avian influenza virus...f the virus. Vaccines based on this model might th... a pandemic (worldwide epidemic) until a new vacci...iant causing the outbreak, the researchers said. A...
Other Biology News:Mussels evolve quickly to defend against invasive crabs 2Mussels evolve quickly to defend against invasive crabs 3UN review shows need to halt destructive fishing practice 2Scientists to employ Arctic ice and polar bears to protect diversity of world's crops 2
(Date:11/25/2009)...FirstCall/--ArdeaBiosciences,Inc.(Nasdaq: RDEA )an...chiefexecutiveofficer,willpresentatthePiperJaffray...tailsareasfollows:,PiperJaffray21stAnnualHealthCa...p.m.EasternTime,Location:TheNewYorkPalaceHotel,New...t/ireye/,target=,_blank,title=,http://www.corpora...
(Date:11/24/2009)...irstCall/--IES(Nasdaq: IESC ),aleadingnationalprov...sforthecommercial,industrialandresidentialmarkets,...nawardedacontractfromManhattanTorconJVtoinstallthe...eplacementfacilityattheU.S.ArmyMedicalResearchInst...Frederick,Md. ,, ThenewUSAMRIIDreplacementfacil...
(Date:11/24/2009)...ork investment bank KTA Capital,s client Neuren Ph...il convertible note private placement with a U.S. ...arranged by KTA Capital as Neuren,s exclusive plac... New York (PRWEB) November 23, 2009 -- The indepe...quot;KTA Capital") has announced that its cli...
(Date:11/24/2009)...Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCanad...,adivisionofThompsonsLimitedofBlenheim,Ontario.The...ces,currentseedsbusinessasthecompanyanticipatesthe...ciencesHerbicideTolerantTraitTechnologyincornin201...,, "Thisacquisitionbringstogethertwostrongprogr...
Breaking Biology Technology:Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...signed to develop,educational opportunities for st...Tiger Woods Learning Center (TWLC) are collaborati.... "A recent report by the National,Research Counci...gued that,students are more likely to have increas...ipate in hands-on experiences," says Jeff Harford,...
...ticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.c...ced today that it has been selected to display its...acodynamics (PD) of Oral Insulin in,Healthy Subjec...Association,s Scientific Sessions Conference in Sa...rom its oral insulin trials on healthy volunteers....
... numerous,shareholder questions, CEL-SCI CORPORATI...struction of its manufacturing facility near Balti... will comprise 73,000 square,feet and will be used...ancer product. This dedicated facility will produc...votal Phase III clinical trial for first-line,ther...
Other Biology Technology:LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics 2Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco) 2Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco) 3CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 2CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 3
Tissue Block Controls from QualTek Molecular Laboratories
Tramadol ELISA Kit, Single from Bio-Quant Inc.
METHAMPHETAMINE ELISA Kit, Single from Bio-Quant Inc.
Fentanyl ELISA Kit, Single from Bio-Quant Inc.
Biology Products: